• OFID 2018:5 (Suppl 1) • Poster Abstracts studied the clinical characteristics of staphylococcus aureus catheter-related septic thrombosis as well as the appropriate management and duration of treatment.
Background. Blood stream infections due to Candida auris is a significant public health concern due to increased patient mortality, frequent misidentification, and high rates of antifungal resistance. C. auris is known to be azole resistant, however several strains have been identified with elevated MICs to all classes of antifungals. Current treatment options for a pan-resistant strain of C. auris would be extremely challenging. Previously we have shown that non-antibiotic, Nitroglycerine + Citrate + Ethanol (NiCE) lock solution was highly efficacious in eradicating various species of multi-drug-resistant Candida. In this study we compared the efficacy of NiCE with standard of care antifungals commonly used in lock solutions in eradicating C. auris biofilms.
Methods. Biofilm eradication of C. auris was evaluated in 10 strains. Candida auris biofilm was grown on silicone discs for 24 hours. Discs were then washed to remove any non-adherent organisms and exposed for 2 hours to various antifungal lock solutions including NiCE, Echinocandins, Azoles, and Amphotericin B. Discs were exposed to Muller-Hinton broth as a control. Subsequently discs were sonicated for 15 minutes in 5 mL of saline and quantitatively cultured onto sabouraud dextrose agar. Plates were incubated at 37°C for 48 hours and counted for growth. All testing was conducted with 6 replicates.
Results. NiCE and Caspofungin were significantly more effective in eradicating C. auris biofilms compared with control (P = 0.002 and 0.008, respectively). However, Caspofungin failed to eradicate a few strains of C. auris biofilm while NiCE completely eradicated all 10 strains. Micafungin, Anidulafungin, Fluconazole, and Voriconazole were not significantly different than control (P > 0.05) for all strains.
Conclusion. NiCE catheter lock solution was capable of completely eradicating all C. auris biofilms within 2 hours indicating high potential for preventing CRBSI caused by C. auris. Caspofungin eradicated some strains of C. auris biofilm, but failed to eradicate all. Other commonly used antifungals were no different than control. Future clinical studies to verify these findings need to be conducted. Background. Central venous access devices (CVAD) are essential for long-term intra-venous treatment of malignancies and other conditions. Catheter-related infections (CRI) complicate long-term CVAD use at rates between 1.5 and 5%, resulting in significant morbidity and mortality. Current evidence does not support a role for antibiotic prophylaxis pre-insertion. We aim to determine rates of CRIs complicating CVAD insertions by vascular surgery and interventional radiology in a single institution and examine the role of antibiotic prophylaxis in prevention.
Methods. A retrospective audit was carried out on CVAD insertions (tunnelled central venous catheter (CVC) or subcutaneous port) by the Vascular Surgery and Radiology Departments at a tertiary teaching hospital in Sydney, Australia from January 2014 to December 2016. Data were collected on patient demographics, antibiotic prophylaxis, skin preparation and CRIs. Rates of CRIs were compared by chisquare test (α 0.05).
Results. Ninety-five (11 tunnelled CVC; 84 subcutaneous ports) and 222 (21 tunnelled CVC; 201 subcutaneous ports) CVAD insertions were performed by vascular surgery and radiology, respectively. Median age was 56 years (IQR 48-66) in the vascular cohort and 64 years (IQR 55-72) in the radiology cohort. Females were predominant in both vascular (70; 73.7%) and radiology (119, 53.6%) cohorts and the most common indication was chemotherapy (vascular 84; 88.4% and radiology 205; 92.8%, n = 1 missing). Antibiotic prophylaxis was used in 88 (92.6%) vascular insertions but only 2 (0.95%, n = 12 missing) insertions by radiology. Iodine skin preparation was preferred for vascular insertions (92; 98.9%, n = 2 missing) compared with chlorhexidine for radiology insertions (214; 97.7%, n = 3 missing). CRIs occurred in 4 (4.2%) of the vascular cohort and 8 (3.6%) of radiology cohort (P = 0.80).
Conclusion. Rates of CRIs complicating CVAD procedures were similar in a vascular cohort where most received antibiotic prophylaxis, and in a radiology cohort where antibiotic prophylaxis was rarely used. There was no evidence to support antibiotic prophylaxis in prevention of CRIs, although choice of skin preparation and other factors may have confounded findings.
Disclosures. All authors: No reported disclosures. Background. Although PICCs are important for venous access, they pose risk of infection, venous thrombosis, and are costlier relative to other forms of vascular access. We conducted a preliminary quality improvement study to assess the indications for PICC placement at our institution and also to evaluate the associated healthcare cost.
Peripherally Inserted Central Catheter (PICC) Placement
Methods. We obtained data on all PICCs placed by the vascular access team over a representative 2-month period (November and December 2017) at Allegheny General Hospital. Indications entered during order entry for PICC placement were collected. Additionally, charts of all central line-associated blood stream infections (CLABSI) in 2017 were reviewed to determine the number of events where PICC may have been implicated. We calculated the cost incurred for PICC placement and that for treating infection in PICC-associated CLABSI. The cost of each PICC insertion is about $4,700 and that of each CLABSI approximates $25,000.
Results. A total of 451 PICCs were inserted over the 2-month period. Documented indications for PICC insertion included: "poor venous access" (128, 28.3%), "receiving high-risk drugs" (91, 20%), "requires multiple simultaneous IV infusions" (84, 18.6%), "needed upon discharge for long-term use" (63, 13.9%), and "receiving vasopressors, total parental nutrition or chemotherapy" (61, 13.6%). There was no indication described for 23 PICC orders (5.2%). Twenty-five CLABSI were encountered in 2017; 10 of them were PICC associated. Of those, PICC was not absolutely indicated in two patients based on chart review (with cost burden of about $65,000 in these two instances).
Conclusion. Poor venous access and multiple IV infusions are not absolute indications for PICC insertion in most circumstances. In our study, this amounted to nearly half (212/451) of the indications for PICC placement. Our hospital could have potentially saved a million dollars in the 2-month study period if PICCs were not placed for these indications. Given the costs and risks associated with PICC use, alternative venous access devices should be strongly considered. By rigorously reevaluating indications for PICC use we may improve both patient outcomes and reduce healthcare costs.
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